Tri-GalNAc(OAc)3-Perfluorophenyl

SKU HY-145368B-10 mg Category Tags , ,

$2,950

Only 1000 item(s) left in stock.

Products Details

Product Description

– Tri-GalNAc(OAc)3-Perfluorophenyl is a pentafluorophenyl modified Tri-GalNAc(OAc)3 (HY-148118), a tri-GalNAc ligand that can be used for the synthesis of GalNAc-LYTAC. GalNAc-LYTAC engages the asialoglycoprotein receptor for targeted protein degradation. tri-GalNAc: triantenerrary N-acetylgalactosamine; LYTAC: lysosome-targeting chimera[1].

Web ID

– HY-145368B

Storage Temperature

– -20°C (Powder, stored under nitrogen)

Shipping

– Blue Ice

Molecular Formula

– C99H151F5N10O44

References

– [1]Zhou Y, et al. Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins. ACS Cent Sci. 2021 Mar 24;7(3):499-506.

Molecular Weight

– 2280.29

Compound Purity

– 95.0

SMILES

– O=C(CCOCCOCCOCCOCCOCCC(OC1=C(F)C(F)=C(F)C(F)=C1F)=O)NC(COCCC(NCCCNC(CCCCO[C@H](O[C@@H]2COC(C)=O)[C@@H]([C@H]([C@H]2OC(C)=O)OC(C)=O)NC(C)=O)=O)=O)(COCCC(NCCCNC(CCCCO[C@H](O[C@@H]3COC(C)=O)[C@@H]([C@H]([C@H]3OC(C)=O)OC(C)=O)NC(C)=O)=O)=O)COCCC(NCCCNC(CCCCO[C@H](O[C@@H]4COC(C)=O)[C@@H]([C@H]([C@H]4OC(C)=O)OC(C)=O)NC(C)=O)=O)=O

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– 10 mM in DMSO|DMSO : 50 mg/mL (ultrasonic)

Target

– LYTACs

Pathway

– PROTAC

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=